TY  - BOOK
AU  - Dahagam, Chanukya R
TI  - Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A Critique [Review]
SN  - 0002-9343
PY  - 2016///
KW  - *Dyslipidemias/pc [Prevention & Control]
KW  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
KW  - *Practice Guidelines as Topic
KW  - *United States Department of Defense/st [Standards]
KW  - *United States Department of Veterans Affairs/st [Standards]
KW  - Biomarkers/an [Analysis]
KW  - Calcium/an [Analysis]
KW  - Cardiovascular Diseases/pc [Prevention & Control]
KW  - Coronary Vessels/ch [Chemistry]
KW  - Humans
KW  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/ad [Administration & Dosage]
KW  - Lipids/bl [Blood]
KW  - United States
KW  - MedStar Franklin Square Medical Center
KW  - Medicine
KW  - Journal Article
KW  - Review
N1  - Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - present
N2  - Copyright © 2016 Elsevier Inc. All rights reserved; In December 2014, the US Department of Veterans Affairs and Department of Defense (VA/DoD) published an independent clinical practice guideline for the management of dyslipidemia and cardiovascular disease risk, adding to the myriad of recently published guidelines on this topic. The VA/DoD guidelines differ from major US guidelines published by the American College of Cardiology/American Heart Association in 2013 in the following ways: recommending moderate-intensity statins for the majority of patients with statin indications regardless of atherosclerotic cardiovascular disease risk; advocating for limited on-treatment lipid monitoring; and deemphasizing ancillary data, such as coronary artery calcium testing, to improve atherosclerotic cardiovascular disease risk estimation. In the context of manifold treatment recommendations from numerous guideline committees, the VA/DoD recommendations may generate further confusion and mixed messages among healthcare providers about the optimal treatment of dyslipidemia. In this review, we critically appraise the VA/DoD recommendations with a focus on the evidence base for each area where the VA/DoD guidelines differ from the American College of Cardiology/American Heart Association guidelines. We also call for harmonization of lipid treatment guidelines to ensure high-quality and consistent care for patients with, and at risk for, atherosclerotic cardiovascular disease.
UR  - https://dx.doi.org/10.1016/j.amjmed.2016.04.012
ER  -